Circulating non-coding RNAs in biomarker-guided cardiovascular therapy: a novel tool for personalized medicine?
Circulating non-coding RNAs in biomarker-guided cardiovascular therapy: a novel tool for personalized medicine?
复制标题
DOI：
10.1093/eurheartj/ehy234
复制
发表时间：
2019-05-21
影响因子：
39.3
通讯作者：
Thum T
中科院分区：
文献类型：
--
作者：
de Gonzalo-Calvo D;Vea A;Bär C;Fiedler J;Couch LS;Brotons C;Llorente-Cortes V;Thum T
目前的临床指南强调了对技术创新的未满足需求，以指导医生的决策，并从传统护理过渡到个性化心血管医学。生物标志物引导的心血管治疗代表了一种有趣的方法，为量身定制的治疗选择和监测持续的疗效提供信息。然而，先前发表的结果对生物标志物指导个体化治疗的临床适用性提出了一些质疑。近年来，非编码人类转录组为开发新的治疗策略和发现生物标志物提供了新的机会。非编码RNA （ncRNA）特征可以提供患者表型的准确分子指纹，并捕获可以补充传统标记和已建立的临床变量的信息水平。重要的是，已经在体液中发现了ncrna，它们的浓度随着生理和病理的变化而变化，因此代表了有希望的非侵入性生物标志物。先前的出版物强调了循环ncrna在心脏病学诊断和预后分层中的翻译适用性。许多独立研究也评估了循环非编码转录组预测和监测心血管治疗反应的潜力。然而，这一领域尚未得到详细的审查。在这里，我们讨论了循环ncrna的最新研究，特别是microrna和长链非编码rna，以支持心血管治疗的临床决策。此外，我们总结了目前的方法和概念上的局限性，并提出了将其纳入个性化心脏病学的未来步骤。尽管缺乏强有力的基于人群的研究和技术障碍，循环ncrna成为生物标志物引导治疗的有前途的工具。
Current clinical guidelines emphasize the unmet need for technological innovations to guide physician decision-making and to transit from conventional care to personalized cardiovascular medicine. Biomarker-guided cardiovascular therapy represents an interesting approach to inform tailored treatment selection and monitor ongoing efficacy. However, results from previous publications cast some doubts about the clinical applicability of biomarkers to direct individualized treatment. In recent years, the non-coding human transcriptome has emerged as a new opportunity for the development of novel therapeutic strategies and biomarker discovery. Non-coding RNA (ncRNA) signatures may provide an accurate molecular fingerprint of patient phenotypes and capture levels of information that could complement traditional markers and established clinical variables. Importantly, ncRNAs have been identified in body fluids and their concentrations change with physiology and pathology, thus representing promising non-invasive biomarkers. Previous publications highlight the translational applicability of circulating ncRNAs for diagnosis and prognostic stratification within cardiology. Numerous independent studies have also evaluated the potential of the circulating non-coding transcriptome to predict and monitor response to cardiovascular treatment. However, this field has not been reviewed in detail. Here, we discuss the state-of-the-art research into circulating ncRNAs, specifically microRNAs and long non-coding RNAs, to support clinical decision-making in cardiovascular therapy. Furthermore, we summarize current methodological and conceptual limitations and propose future steps for their incorporation into personalized cardiology. Despite the lack of robust population-based studies and technical barriers, circulating ncRNAs emerge as a promising tool for biomarker-guided therapy.
登录
查看更多内容
影响因子：
21.3
作者：
Hergenreider, Eduard;Heydt, Susanne;Dimmeler, Stefanie
通讯作者：
Dimmeler, Stefanie
影响因子：
8.9
作者：
Feldman, David;Pamboukian, Salpy V.;Rogers, Joseph
通讯作者：
Rogers, Joseph
影响因子：
3.3
作者：
de Gonzalo-Calvo, David;Davalos, Alberto;Iglesias-Gutierrez, Eduardo
通讯作者：
Iglesias-Gutierrez, Eduardo
影响因子：
18.2
作者：
Dickinson, Brent A.;Semus, Hillary M.;van Rooij, Eva
通讯作者：
van Rooij, Eva
影响因子：
4.6
作者：
de Gonzalo-Calvo D;van der Meer RW;Rijzewijk LJ;Smit JW;Revuelta-Lopez E;Nasarre L;Escola-Gil JC;Lamb HJ;Llorente-Cortes V
通讯作者：
Llorente-Cortes V